temozolomide has been researched along with rg7388 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berry, P; Bonner, J; Chen, L; Daga, A; Kirk, C; Lunec, J; Newell, DR; Pastorino, F; Ponzoni, M; Thomas, HD; Tweddle, DA; Veal, GJ; Wood, KM; Zhao, Y | 1 |
| Ayyagari, P; Das, SK; Pollok, KE; Shannon, HE; Smiley, SB; Vannier, MW; Veronesi, MC; Yun, Y | 1 |
2 other study(ies) available for temozolomide and rg7388
| Article | Year |
|---|---|
Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Mice; Neuroblastoma; para-Aminobenzoates; Prodrugs; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Random Allocation; Temozolomide; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2019 |
Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma - In Vitro Evaluation in Glioblastoma Stem Cells.
Topics: AC133 Antigen; Animals; Brain Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Development; Drug Evaluation, Preclinical; Glioblastoma; Humans; Mice; Micelles; Nanoparticles; Neoplastic Stem Cells; para-Aminobenzoates; Polymers; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Temozolomide | 2021 |